|
|
|
|
Second Life avatar first virtual item tradmarked
Cara Therapeutics wins patent for new opioid painkiller [July 22, 2008] Tech Citizenship: Tech Citizenship [June 13, 2008] Tech Citizenship: Tell about your giving with social media [November 21, 2008] Mintz Levin represents West Coast...
|
|
|
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
RARITAN, N.J., Nov.21 /PRNewswire/ -- Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option. Today, Johnson & Johnson Pharmaceutical Research &...
|
|
|
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
/PRNewswire/ -- Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option.Today, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&...
|
|
|
Johnson & Johnson Pharmaceutical Research & Development (JNJ) Receives FDA Approval for Tapentadol Immediate-R
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (NYSE: JNJ) announced that the U.S.Food and Drug Administration (FDA) approved tapentadol immediate-release tablets for the relief of moderate to severe acute pain...
|
|
|
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
RARITAN, N.J., Nov.21 /PRNewswire/ -- Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option. Today, Johnson & Johnson Pharmaceutical Research & Development...
|
|
|
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
RARITAN, N.J., Nov.21 /PRNewswire/ -- Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option. Today, Johnson & Johnson Pharmaceutical Research & Development...
|
|
|
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
RARITAN, N.J., Nov.21 /PRNewswire/ -- Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option. Today, Johnson & Johnson Pharmaceutical Research & Development...
|
|
|
Neuromed completes enrollment for Phase III chronic low back pain trial
The design of the Phase III trial of NMED-1077 is a randomized withdrawal, placebo-controlled, double-blind trial which is being conducted at multiple centers in the US.The study is evaluating the safety and efficacy of NMED-1077 in 269 ...
|
|
|
Research from University of les Illes Balears reveals new findings on enzyme research
(NewsRx.com) -- Data detailed in 'Opioid receptor agonists enhance the phosphorylation state of Fas-associated death domain (FADD) protein in the rat brain: functional interactions with casein kinase Ialpha, Galpha(i) proteins, and...
|
|
|
US FDA accepts TheraQuest's pain drug IND application
TheraQuest Biosciences, Inc.a development stage pain management company announced that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for TQ-1015, its abuse deterrent extended release...
|
|
|
Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
/PRNewswire/ - Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, announced today it has completed enrollment in the pivotal Phase 3 chronic low back pain clinical trial of NMED-1077 (OROS(R...
|
|
|
New life sciences study findings reported from J. Moss and co-authors
- (NewsRx.com) -- 'The recent approval by the US Food and Drug Administration of 2 medications-methylnaltrexone and alvimopan-introduces a new class of therapeutic entities to clinicians (see also Life Sciences).These peripherally acting...
|
|
|
Tris Pharma's New Tool Fights Against Prescription Drug Abuse
Tris Pharma, a privately owned, specialty pharmaceutical company, today unveiled a key component in the nation's fight against opioid abuse.Its new drug delivery platform, NoBuse(TM), offers a technology by which companies can...
|
|
|
SRI Awarded National Institute on Drug Abuse Contract for Chemical Analysis of Opioid Peptides and Drugs of Ab
SRI International, an independent, nonprofit research and development organization, announced today that it has been awarded a $1,788,011 contract by the National Institute on Drug Abuse (NIDA).The award is a continuation of two previous...
|
|
|
Pharmacology: New pharmacology research from University of Michigan, Department of Pharmacology discussed
New pharmacology research from University of Michigan, Department of Pharmacology discussed (NewsRx.com) -- Researchers detail in 'The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat...
|
|
|
European Medicines Agency Recommends the Suspension of the Marketing Authorisation of Ionsys (fentanyl hydroch
LONDONT, Nov.20, 2008-The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride), from Janssen-Cilag International NV, because of a defect with the delivery system...
|
|
|
Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
Attention Business Editors VANCOUVER, BC and CONSHOHOCKEN, PA, Nov.20 /CNW/ - Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, announced today it has completed enrollment in the pivotal...
|
|
|
BioDelivery Sciences Remains on Schedule for December ONSOLIS Resubmission Following Meeting with FDA
- BioDelivery Sciences International, Inc., (Nasdaq: BDSI) announced that the company continues to anticipate a resubmission containing the Risk Evaluation and Mitigation Strategy (REMS) for its lead product ONSOLIS to the Food and Drug...
|
|
|
BioDelivery Sciences Remains on Schedule for December ONSOLIS Resubmission Following Meeting with FDA
RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc., (Nasdaq: BDSI - News) announced that the company continues to anticipate a resubmission containing the Risk Evaluation and Mitigation Strategy (REMS) for its lead...
|
|
|
Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth
George E.Woody, MD; Sabrina A. Poole, MS; Geetha Subramaniam, MD; Karen Dugosh, PhD; Michael Bogenschutz, MD; Patrick Abbott, MD; Ashwin Patkar, MD; Mark Publicker, MD; Karen McCain, MSN, FNP; Jennifer Sharpe Potter, PhD, MPH; Robert...
|
|
|
Titan Pharmaceuticals Presents Phase 3 Data for Probuphine at the 2008 International Society of Addiction Me
SOUTH SAN FRANCISCO, Calif & CAPE TOWN, South Africa-(Business Wire)-November 19, 2008 - Titan Pharmaceuticals, Inc.(AMEX:TTP) today presented detailed data from its positive Phase 3 placebo controlled study of Probuphine in the...
|
|
|
Titan Pharmaceuticals Presents Phase 3 Data for Probuphine at the 2008 International Society of Addiction Medi
SOUTH SAN FRANCISCO, Calif & CAPE TOWN, South Africa--(BUSINESS WIRE)--Nov 19, 2008 - Titan Pharmaceuticals, Inc.(AMEX:TTP) today presented detailed data from its positive Phase 3 placebo controlled study of Probuphine in the...
|
|
|
Titan Pharmaceuticals Presents Phase 3 Data for Probuphine at the 2008 International Society of Addiction Med
SOUTH SAN FRANCISCO, Calif & CAPE TOWN, South Africa (Business Wire) -- Titan Pharmaceuticals, Inc.(AMEX:TTP) today presented detailed data from its positive Phase 3 placebo controlled study of Probuphine in the treatment of opioid...
|
|
|
Titan Pharmaceuticals Presents Phase 3 Data for Probuphine at the 2008 International Society of Addiction Med
SOUTH SAN FRANCISCO, Calif & CAPE TOWN, South Africa--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc.(AMEX:TTP - News) today presented detailed data from its positive Phase 3 placebo controlled study of Probuphine in the treatment of ...
|
|
|
Titan Pharmaceuticals Presents Phase 3 Data for Probuphine at the 2008 International Society of Addiction Med
Business Editors/Health/Medical Writers SOUTH SAN FRANCISCO, Calif & CAPE TOWN, South Africa--(BUSINESS WIRE)--November 19, 2008--Titan Pharmaceuticals, Inc.(AMEX:TTP) today presented detailed data from its positive Phase 3 placebo...
|
